JAK2 and myeloproliferative disorder: While JAK2VF-driven myeloproliferative disorders are associated with increased hematocrit, platelet and leukocyte counts, mutations in JAK2 exon 12 have been identified in patients with myeloproliferative disorders who have isolated erythrocytosis (9) and increased atherothrombotic events (11).